Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •Unresolved toxicity from prior anticancer therapy of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2 except for those defined by the protocol
• •Participant experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy
• •Previous history of hemophagocytic lymphohistiocytosis (HLH) / macrophage activation syndrome (MAS)
• •Active or prior documented autoimmune or inflammatory disorders within 3 years of start of treatment
• •central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent
• •Infectious disease including active human immunodeficiency virus (HIV), active hepatitis B/C, uncontrolled infection with EBV, uncontrolled active systemic fungal, bacterial or other infection
• •Cardiac conditions as defined by the protocol
• •History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention
• •Participant requires chronic immunosuppressive therapy
• •Participants on anticoagulation therapy with long-acting anticoagulants or other class of anticoagulants at therapeutic doses